1.
Schauer NJ, Liu X, Magin RS, et al. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Sci Rep. 2020;10(1):5324. doi:10.1038/s41598-020-62076-x.
1.
Rees MG, Seashore-Ludlow B, Clemons PA. Computational Analyses Connect Small-Molecule Sensitivity to Cellular Features Using Large Panels of Cancer Cell Lines. Methods Mol Biol. 2019;1888:233-254. doi:10.1007/978-1-4939-8891-4_14.
1.
McCoull W, Cheung T, Anderson E, et al. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. ACS Chem Biol. 2018;13(11):3131-3141. doi:10.1021/acschembio.8b00698.
1.
Oser MG, Fonseca R, Chakraborty AA, et al. Cells Lacking the Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov. 2019;9(2):230-247. doi:10.1158/2159-8290.CD-18-0389.
1.
Hamieh L, Choueiri TK, Ogórek B, et al. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet. 2018;14(9):e1007679. doi:10.1371/journal.pgen.1007679.
1.
Lopes-Ramos CM, Kuijjer ML, Ogino S, et al. Gene Regulatory Network Analysis Identifies Sex-Linked Differences in Colon Cancer Drug Metabolism. Cancer Res. 2018;78(19):5538-5547. doi:10.1158/0008-5472.CAN-18-0454.
1.
Guerra RM, Bird GH, Harvey EP, et al. Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer. Cell Rep. 2018;24(13):3393-3403.e5. doi:10.1016/j.celrep.2018.08.089.
1.
Ubellacker JM, Baryawno N, Severe N, et al. Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer. Cancer Res. 2018;78(18):5300-5314. doi:10.1158/0008-5472.CAN-18-0548.
1.
Izar B, Sharfman W, Hodi S, et al. A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Med. 2017;6(8):1904-1914. doi:10.1002/cam4.1140.
1.
Stover EH, Baco MB, Cohen O, et al. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. Mol Cancer Res. 2019;17(11):2281-2293. doi:10.1158/1541-7786.MCR-18-1243.